Lv5
950 积分 2023-06-12 加入
Amivantamab plus lazertinib vs osimertinib in first-line (1L) EGFR-mutant (EGFRm) advanced NSCLC: Final overall survival (OS) from the phase III MARIPOSA study
1天前
求助中
Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial
8天前
已完结
Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck A Randomized Clinical Trial
13天前
已完结
Curative Application of Immunotherapy in Untreated Head and Neck and Nasopharynx Cancer
13天前
已完结
Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma The DIPPER Randomized Clinical Trial
13天前
已完结
vonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
26天前
已完结
Longer-Term Safety And Efficacy Of Selinexor Maintenance Therapy For Patients With TP53wt Advanced Or Recurrent Endometrial Cancer: Follow-Up Subgroup Analysis Of The ENGOT-EN5/GOG-3055/SIENDO Study
26天前
已关闭
Comparison Of Hybrid Capture 2 Oncogenic HPV Test Performance On Evalyn- Vs Qiagen-Brush Self-Collected Specimens Among A South African Population Enriched For HIV-Positivity
26天前
已关闭
A Single-Arm, Multicenter, Phase II Study On Carboplatin-Paclitaxel-Pembrolizumab In Neoadjuvant Treatment Of Locally Advanced Cervical Cancer: The MITO CERV3 Study
26天前
已完结
Academic Randomized Phase II Trial Assessing The Inhibitor Of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab In Combination With Chemoradiation In Locally Advanced Cervical Cancer (ATEZOLACC Trial)
26天前
已关闭
皖公网安备34019202002308
